Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma

Cancer

Volumn 83, Issue 6, 1998, Pages 1153-1162

  Talvensaari Mattila, Anne ^a   Pääkkö, Paavo ^a   Höyhtyä, Matti ^b   Blanco Sequeiros, Guillermo ^a   Turpeenniemi Hujanen, Taina ^a  

^a UNIVERSITY OF OULU   (Finland)

^b Diabor Oy   (Finland)

Author keywords

Breast carcinoma; Gelatinase A; Matrix metalloproteinase 2; Metastasis; Prognosis; Prognostic factor; Type IV collagenase

Indexed keywords

COLLAGEN TYPE 4; COLLAGENASE; GELATINASE A;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER MORTALITY; CANCER SURVIVAL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION;

AGE FACTORS; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN;

EID: 0032530876     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4     Document Type: Article

References (31)

1. Shetty MR, Reiman HM Jr. Tumor size and axillary metastasis, a correlative occurrence in 1244 cases of breast cancer between 1980 and 1995. Eur J Surg Oncol 1997; 23(2):139-41.
2. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43.
3. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-72.
4. Matrisian LM, McDonnell S, Miller DB, Navre M, Seftor EA, Hendrix MJ. The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci 1991;302:157-62.
5. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284: 67-8.
6. Nakajima M, Welch DR, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987;47: 4869-76.
7. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta LA. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids which differ in metastatic potential. J Natl Cancer Inst 1985; 75:99-103.
8. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990;136:585-92.
9. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67: 1126-31.
10. Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenases in invasive tumours. Breast Cancer Res Treat 1993;24:209-18.
11. Höyhtyä M, Fridman R, Komarck D, Porter-Jordan K, Stetler-Stevenson NG, Liotta LA, et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer 1994;54:500-5.
12. Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini WG, et al. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers, Int J Cancer 1991;48:529-32.
13. Soini Y, Hurskainen T, Höyhtyä M, Oikarinen A, Autio-Harmainen H. 72 kD and 92 kD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 1994;42:945-51.
14. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumour progression. Proc Natl Acad Sci USA 1993;90:1843-7.
15. Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, et al. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 1993;46:429-36.
16. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remacle A, et al. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 1994;424:641-5.
17. Marqulies IMK, Höyhtyä M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG. Urinary type IV collagenase elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev 1992;467-74.
18. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumours. 4th edition. 2nd revision. Berlin: Springer-Verlag, 1992.
19. Scarff RW, Torloni H. Histological typing of breast tumours. Geneva: World Health Organization, 1986.
20. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
21. Hsu SM, Raine L, Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
22. Autio-Harmainen H, Hurskainen T, Niskasaari K, Höyhtyä M, Tryggvason K. Simultaneous expression of 72 kilodalton type IV collagenase and type IV collagen α1(IV) chain genes by cells of early human placenta and gestational endometrium. Lab Invest 1992;67:191-200.
23. Autio-Harmainen H, Karttunen T, Hurskainen T, Höyhtyä M, Kauppila A, Tryggvason K. Expression of 72 kDa type IV collagenase in bening and malignant ovarian tumors. Lab Invest 1993;69:312-21.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in this consideration. Cancer Chemother Rep 1966;50:163-70.
26. Cox DR. Regression models and life-tables. R Stat Soc Ser (B) 1972;34:187-220.
27. Dixon WJ, Brown MB, Engelman L. BMDP statistical software 1990. Berkeley: University of California Press, 1990.
28. Visscher DW, Höyhtyä M, Ottosen SK, Liang C-M, Sarkar FH, Crissman JD. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in stroma of breast carcinomas correlates with tumour recurrence. Int J Cancer 1994; 59:339-44.
29. Kawami H, Yoshida K, Ohsaki A, Kuroi K, Nishiyama M, Toge T. Stromelysin-3 mRNA expression and malignancy: comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res 1993;13:2319-23.
30. Wong WW, Vijayakumar S, Weichselbaum RR. Prognostic indicators in node-negative early stage breast cancer. Am J Med 1992;92:539-48.
31. Fernö M, Baldetorp B, Borg Å, Brouillet J-P, Olsson H, Rochefort H. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 1994;14:2042-8.